Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 3/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 5/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.62 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.62 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.59 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.59 |
| ▸ | ALB | P02768 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.59 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.59 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.58 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.58 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxecitine SCHEMBL29910618 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL30616799 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL15832461 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL887491 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL10238960 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL31503186 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL23346798 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL13700553 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL23178 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL193815 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290533-B2 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B | NOVARTIS AG (CH) | 2016-03-22 | — | — | US | disclosed |
| US-9249173-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, LLC (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140255339-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20120264707-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8158606-B2 | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | NOVARTIS, AG (CH) | 2012-04-17 | — | — | US | disclosed |
| US-20110286962-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. | 2011-11-24 | — | — | US | disclosed |
| US-20110286962-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. | 2011-11-24 | — | — | US | disclosed |
| US-20110257120-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110172178-A1 | BETA-L-2' DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-7951789-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951789-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7795238-B2 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7585851-B2 | 3′-prodrugs of 2′-deoxy-β-L-nucleosides | IDENIX PHARMACEUTICALS, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-20080286230-A1 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
| US-20080286230-A1 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
| US-20080188440-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080064655-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | INDENIX PHARMACEUTICALS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7186700-B2 | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | IDENIX PHARMACEUTICALS, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186700-B2 | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | IDENIX PHARMACEUTICALS, INC. (US) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257120-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | PNP, DUT, ATIC | DNMT1 2009/4885ADRB1 948/4885POLB 65/4885 |
| US-20080286230-A1 | Compounds and pharmaceutical compositions for the treatment of viral infections | HAVCR2, PYGL, GYS2 | DNMT1 2523/4885ADRB1 3793/4885POLB 128/4885 |
| US-20110172178-A1 | BETA-L-2' DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES | SLC28A2, SLC29A2, PNP | DNMT1 120/4885ADRB1 1450/4885POLB 66/4885 |
| US-20140255339-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, PYGL, GYS2 | DNMT1 2523/4885ADRB1 3793/4885POLB 128/4885 |
| US-20080188440-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | PNP, DUT, ATIC | DNMT1 2009/4885ADRB1 948/4885POLB 65/4885 |
| US-20080064655-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | ATIC, SLC35B2, AASDHPPT | DNMT1 1660/4885ADRB1 1417/4885POLB 131/4885 |
| US-20120264707-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | PNP, DUT, ATIC | DNMT1 2009/4885ADRB1 948/4885POLB 65/4885 |
| US-20110286962-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, PYGL, GYS2 | DNMT1 2523/4885ADRB1 3793/4885POLB 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.